Regencell Bioscience Holdings Limited (NASDAQ:RGC - Get Free Report)'s share price gapped down prior to trading on Monday . The stock had previously closed at $14.75, but opened at $14.30. Regencell Bioscience shares last traded at $15.15, with a volume of 290,187 shares changing hands.
Regencell Bioscience Trading Down 0.5%
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Regencell Bioscience stock. Greenfield Savings Bank acquired a new position in shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,000 shares of the company's stock, valued at approximately $187,000. 0.13% of the stock is owned by institutional investors and hedge funds.
Regencell Bioscience Company Profile
(
Get Free Report)
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.
Read More
Before you consider Regencell Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regencell Bioscience wasn't on the list.
While Regencell Bioscience currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
